郑文婷，研究员，博士研究生导师，研究方向聚焦于免疫细胞行为的工程化改造及肿瘤治疗应用，重点围绕“工程化方法赋能免疫细胞用于肿瘤治疗”开展研究。运用小鼠和人免疫细胞治疗模型、CRISPR-Cas9筛选技术等探索赋能免疫细胞的新靶点和策略，应用工程化的研究手段改造细胞疗法的功能元件，利用新型生物材料靶向性改造疾病微环境，优化免疫细胞功能，改善肿瘤治疗。 老虎机游戏引进人才，2021年加入老虎机游戏，曾在美国St. Jude Children’s Research Hospital从事博士后研究。

长期从事免疫细胞治疗肿瘤的研究，针对现行的细胞疗法易复发、患者生存率低等临床问题，未来将在“免疫细胞行为的工程化改造及肿瘤治疗应用”领域，充分利用多学科交叉的优势，重点围绕“工程化方法赋能T细胞用于肿瘤治疗”开展研究，以期解决肿瘤精准治疗和难治复发的难题。承担国自然青年项目，以第一/通讯作者在 J Immunother Cancer、Blood、Leukemia、Adv Funct Mater、JACS 等刊物上发表十余篇论文，总引1700余次，获得国际专利2项。

老虎机游戏

1.Wei Liu#, Wei Liu#, Hesong Zou#, Lianting Chen#, Wenyang Huang, Rui lv, Yan Xu, Huimin Liu, Yin Shi, Kefei Wang, Yi Wang, Wenjie Xiong, Shuhui Deng, Shuhua Yi, Weiwei Sui, Guangxin Peng, Yueshen Ma, Huijun Wang, Lulu Lv, Jianxiang Wang, Jun Wei*, Lugui Qiu*, Wenting Zheng*, Dehui Zou*. Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma. Journal for ImmunoTherapy of Cancer, 2024 Apr 16;12(4): e008857.

2.Xiaoyan Zhang#, Kefei Wang#, Zhiyuan Gao, Zelin Wu, Wei Liu, Jisen Li, Heqi Gao, Jun Wei, Dan Ding*, Wenting Zheng*. An Aggregation-Induced Emission Molecule-Assembled Nanovaccine with Self-Adjuvanted Function for Cancer Immunotherapy, Advanced Functional Materials, 2023, 33(51): 2302118.

3. Yiming Zhang#, Zhiwen Hu, Xinxin Li, Yinghao Ding, Zhenghao Zhang, Xiangyang Zhang, Wenting Zheng*, Zhimou Yang*. Amino acid sequence determines the adjuvant potency of a D-Tetra-Peptide hydrogel, Biomaterials Science, 2022 Jun 14;10(12):3092-3098.

4. Wenting Zheng#, Jun Wei, Caitlin Zebley, Lindsay L Jones, Yogesh Dhungana, Yong-Dong Wang, Jayadev Mavuluri, Lingyun Long, Yiping Fan, Benjamin Youngblood, Hongbo Chi, Terrence L Geiger*. Regnase-1 suppresses TCF-1+ precursor exhausted T cell formation to limit CAR T cell responses against ALL, Blood, 2021, 138(2): 122-135.

5.Wenting Zheng#, Carol E. O'Hear, Rajshekhar Alli, Jacob H. Basham, Hossam A. Abdelsamed, Lance E. Palmer, Lindsay L. Jones, Ben Youngblood, Terrence L. Geiger*. PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells, Leukemia, 2018, 32: 1157-1167.